Actively Recruiting

Phase Not Applicable
Age: 40Years +
All Genders
NCT06383247

The Efficacy and Safety of Precision REpetitive Transcranial Magnetic Stimulation in Alleviating Motor Symptom in Parkinson's Disease

Led by Anhui Medical University · Updated on 2025-06-17

290

Participants Needed

1

Research Sites

212 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive and widely used neuromodulation technology. Small sample studies have shown that rTMS treatment can significantly improve the symptoms of Parkinson's disease(PD) and delay the progression of the disease. In order to further explore the effectiveness of rTMS in the treatment of PD and lay the foundation for its clinical promotion, our research team plans to conduct a randomized double-blind controlled study of rTMS in the treatment of PD in multiple centers across the country.

CONDITIONS

Official Title

The Efficacy and Safety of Precision REpetitive Transcranial Magnetic Stimulation in Alleviating Motor Symptom in Parkinson's Disease

Who Can Participate

Age: 40Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 40 years or older
  • Diagnosed with idiopathic Parkinson's disease according to MDS criteria (2015 Edition)
  • No drug adjustments within 4 weeks before treatment and during the entire study
  • MDS-UPDRS Part II score of 8 or higher and Hoehn-Yahr stage 1 to 4
  • MMSE score of 22 or higher and able to cooperate with behavioral tests and rTMS therapy
Not Eligible

You will not qualify if you...

  • Previous head MRI or CT showing focal brain injury or severe leukoencephalopathy (Fazekas grade 3 or higher)
  • Having secondary parkinsonism syndromes such as vascular or drug-induced parkinsonism
  • History of severe head trauma, brain surgery, or deep brain stimulation treatment
  • Presence of ferromagnetic implants like cochlear implants or cardiac pacemakers
  • History of epilepsy, unexplained loss of consciousness, or current use of anticonvulsant drugs
  • Diagnosis of neuropsychiatric disorders other than Parkinson's disease
  • History of drug abuse or drug use
  • Participation in any clinical trial within the past 6 months
  • Pregnant or breastfeeding women or those planning pregnancy within 6 months
  • Any other conditions considered unsuitable by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Cognitive Neuropsychology Lab Anhui Medical University

Hefei, Anhui, China, 230032

Actively Recruiting

Loading map...

Research Team

P

Panpan Hu, M.D.

CONTACT

K

Kai Wang, Ph.D.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here